MEDIUM confidence: 100% data completeness, but the composite (45) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$36.7M over 180 days (0 open-market buys, 44 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Avg target $106 (last qtr, 10 analysts) → $106 (last mo, 6) (+0.6%).
Buy-rated share 92% → 91% over ~3 months (-1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $-0.58 | $-0.78 | -35.5% |
| May 2026 | $-0.68 | $-0.84 | -23.8% |
| Feb 2026 | $-0.71 | $-1.00 | -40.2% |
| Oct 2025 | $-0.88 | $-0.95 | -8.0% |
| Aug 2025 | $-0.83 | $-0.95 | -14.5% |
| Apr 2025 | $-1.00 | $-0.88 | +12.0% |
| Feb 2025 | $-1.09 | $-1.31 | -20.2% |
| Nov 2024 | $-1.03 | $-0.86 | +16.5% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $70M— | $78M+11.4% | $9M-88.0% | $222M+2285.3% | $502M+126.3% |
| EPS (dil.) | $-3.90— | $-3.35n/m | $-3.95n/m | $-2.88n/m | $-3.79n/m |
| Free Cash Flow | -$546M— | -$426Mn/m | -$529Mn/m | -$522Mn/m | -$447Mn/m |
| Gross Margin | 95.5% | 95.6%+0.0pp | 73.7%-21.9pp | 98.3%+24.5pp | 94.4%-3.9pp |
| Operating Margin | -827.1% | -659.6%+167.5pp | -6528.8%-5869.1pp | -267.2%+6261.5pp | -113.3%+153.9pp |
| Net Margin | -806.9% | -619.7%+187.2pp | -6913.9%-6294.2pp | -241.4%+6672.5pp | -145.3%+96.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
The QScore of 45 for BBIO suggests a neutral outlook, driven by a divergence between its long-term and short-term scores, with the latter being 14 points higher. The stock scores high on growth and risk, with revenue growth of 126.3% and a beta of 1.0, respectively. However, it trades at a significant discount due to poor value metrics, including a negative P/E and EV/EBITDA, and exhibits weak profitability, with an operating margin of -78.6%. The stock's momentum is strong, with a 12-month return of 69.0% and a bullish 50-day versus 200-day moving average crossover.